As Bristol (BMY) Share Price Rose, Shareholder Burns J W & Co INC Cut Holding

September 16, 2018 - By Darrin Black

Bristol-Myers Squibb Company (NYSE:BMY) LogoInvestors sentiment decreased to 0.78 in Q2 2018. Its down 0.05, from 0.83 in 2018Q1. It dropped, as 94 investors sold BMY shares while 550 reduced holdings. 108 funds opened positions while 396 raised stakes. 1.14 billion shares or 1.65% more from 1.12 billion shares in 2018Q1 were reported. Edge Wealth Management Lc owns 380 shares for 0.01% of their portfolio. Decatur Capital Mngmt invested in 152,235 shares or 1.67% of the stock. Thrivent Financial For Lutherans has invested 0.01% in Bristol-Myers Squibb Company (NYSE:BMY). Kentucky Retirement System Insurance Trust Fund reported 0.41% in Bristol-Myers Squibb Company (NYSE:BMY). Fairfield Bush & has 16,383 shares. Trustmark State Bank Trust Department has invested 0.44% in Bristol-Myers Squibb Company (NYSE:BMY). Carret Asset Mngmt has 0.35% invested in Bristol-Myers Squibb Company (NYSE:BMY). Dillon Associates Incorporated reported 0.12% in Bristol-Myers Squibb Company (NYSE:BMY). Asset Strategies Inc, New York-based fund reported 4,502 shares. Meritage Portfolio Management owns 116,894 shares. Horizon Kinetics Llc, New York-based fund reported 45,900 shares. Lifeplan Fin Grp Inc has 3,542 shares. Boston Advsrs Limited Liability Company accumulated 79,933 shares or 0.11% of the stock. Haverford Comm owns 81,544 shares or 0.09% of their US portfolio. M&R Mgmt Incorporated, a New York-based fund reported 30,144 shares.

Since April 30, 2018, it had 1 buying transaction, and 0 selling transactions for $249,948 activity.

Burns J W & Co Inc decreased its stake in Bristol (BMY) by 46.05% based on its latest 2018Q2 regulatory filing with the SEC. Burns J W & Co Inc sold 65,024 shares as the company’s stock rose 12.85% with the market. The institutional investor held 76,176 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $4.22 million, down from 141,200 at the end of the previous reported quarter. Burns J W & Co Inc who had been investing in Bristol for a number of months, seems to be less bullish one the $99.04B market cap company. The stock decreased 0.16% or $0.1 during the last trading session, reaching $60.69. About 3.89 million shares traded. Bristol-Myers Squibb Company (NYSE:BMY) has declined 4.27% since September 16, 2017 and is downtrending. It has underperformed by 19.89% the S&P500.

Analysts await Bristol-Myers Squibb Company (NYSE:BMY) to report earnings on October, 25. They expect $0.89 earnings per share, up 18.67 % or $0.14 from last year’s $0.75 per share. BMY’s profit will be $1.45B for 17.05 P/E if the $0.89 EPS becomes a reality. After $1.01 actual earnings per share reported by Bristol-Myers Squibb Company for the previous quarter, Wall Street now forecasts -11.88 % negative EPS growth.

More notable recent Bristol-Myers Squibb Company (NYSE:BMY) news were published by: which released: “Bristol-Myers Squibb’s TYK2 inhibitor successful in mid-stage psoriasis study” on September 12, 2018, also with their article: “Why Yervoy’s Resurgence Will Gain Momentum” published on August 27, 2018, published: “Natera (NTRA) Enters Agreement with Bristol-Myers (BMY) for Signatera ctDNA Assay” on September 13, 2018. More interesting news about Bristol-Myers Squibb Company (NYSE:BMY) were released by: and their article: “Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Morgan Stanley 16th Annual Global …” published on September 13, 2018 as well as‘s news article titled: “Short Sellers Back Off Major Pharma Stocks” with publication date: September 13, 2018.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Among 11 analysts covering Bristol Myers (NYSE:BMY), 2 have Buy rating, 0 Sell and 9 Hold. Therefore 18% are positive. Bristol Myers had 14 analyst reports since March 20, 2018 according to SRatingsIntel. The rating was maintained by BMO Capital Markets with “Market Perform” on Monday, July 23. Bank of America maintained the stock with “Neutral” rating in Tuesday, April 17 report. Morgan Stanley downgraded the shares of BMY in report on Tuesday, April 17 to “Equal-Weight” rating. The rating was maintained by Guggenheim with “Buy” on Tuesday, April 17. The firm has “Hold” rating given on Friday, March 23 by Jefferies. The firm has “Market Perform” rating given on Friday, April 27 by BMO Capital Markets. UBS downgraded the shares of BMY in report on Monday, May 21 to “Hold” rating. Cowen & Co maintained the shares of BMY in report on Friday, April 20 with “Hold” rating. On Friday, April 13 the stock rating was maintained by Jefferies with “Hold”. The stock of Bristol-Myers Squibb Company (NYSE:BMY) has “Neutral” rating given on Wednesday, August 8 by Atlantic Securities.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.